MAP4K4 and diabetes mellitus: Knockdown of MAP4K4 or treatment with a MAP4K4 inhibitor (DMX-5804) inhibited SNO-Drp1 and protected endothelial cells and cardiac microcirculation against diabetes by enhancing mitochondrial functions and suppressing oxidative stress injury and ferroptosis.